Core Insights - Edesa Biotech, Inc. has announced that its CEO, Dr. Par Nijhawan, will deliver the inaugural presentation at the ATS 2026 Respiratory Innovation Summit, highlighting the significance of the company's Phase 3 study results for paridiprubart, an anti-TLR4 antibody for treating Acute Respiratory Distress Syndrome (ARDS) [1][2][3] Company Overview - Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, with a clinical pipeline targeting Medical Dermatology and Respiratory conditions [6] - The company is developing paridiprubart (EB05) as a treatment for ARDS, a condition that leads to over three million ICU admissions globally each year [2][6] Clinical Study Details - The Phase 3 study of paridiprubart has reported results from an initial cohort of 104 patients requiring invasive mechanical ventilation, followed by expanded results from a total of 278 patients, indicating potential clinical benefits [2] - Dr. Ted Steiner, the principal investigator of the Phase 3 study, will present comprehensive results at the ATS 2026 International Conference on May 20, 2026 [4] Presentation Significance - Dr. Nijhawan expressed that being invited to lead the innovation showcase is a validation of the strength of the Phase 3 data and the potential of paridiprubart to transform ARDS treatment, which currently has limited effective options [3] Therapeutic Mechanism - Paridiprubart represents a new class of host-directed therapeutics designed to modulate the immune response against various public health threats, including infectious diseases and other emergencies [5]

Core Viewpoint - Edesa Biotech, Inc. has announced positive results from a Phase 3 study of paridiprubart, demonstrating significant reductions in 28-day mortality across a broad patient population, which has led to increased stock performance and interest in the company's therapeutic potential [1][2][3]. Study Results - The Phase 3 study included a total of 278 patients, combining previously reported 104 patients requiring invasive mechanical ventilation (IMV) and 174 non-IMV patients [3][4]. - Paridiprubart reduced adjusted 28-day mortality from 33% to 24%, representing a 27% relative reduction in the risk of death (p<0.001) [4]. - In a subgroup of 174 patients not requiring IMV, paridiprubart + standard of care (SOC) reduced adjusted 28-day mortality from 23% to 15%, a 35% relative reduction (p<0.05) [5]. Safety and Efficacy - The safety profile of paridiprubart was consistent with prior clinical exposures, with low rates of adverse events and serious adverse events similar to the placebo group [6]. - Exploratory analyses indicated consistent reductions in adjusted mortality for paridiprubart + SOC compared to placebo + SOC across patients with significant comorbidities [6]. Intellectual Property and Future Plans - Edesa has filed provisional patent applications for the use of paridiprubart in treating sepsis, acute kidney injury, and pneumonia, with core patents extending into the 2030s [7]. - The CEO emphasized the potential of paridiprubart to address multiple critical unmet medical needs and mentioned ongoing regulatory discussions and strategic collaborations to accelerate development [9].

Core Viewpoint - Edesa Biotech, Inc. is advancing its clinical programs, particularly in dermatology and respiratory diseases, while reporting a net loss for the first quarter of 2026, reflecting ongoing investments in drug development and manufacturing [1][5]. Financial Performance - Total operating expenses increased by $0.4 million to $2.3 million for the three months ended December 31, 2025, compared to $1.9 million for the same period in the previous year [4]. - Edesa reported a net loss of $2.2 million, or $0.28 per common share, for the quarter ended December 31, 2025, compared to a net loss of $1.6 million, or $0.48 per common share, for the same quarter in 2024 [5][13]. - Cash and cash equivalents at December 31, 2025, were $12.1 million, with working capital of $12.0 million [6]. Drug Development Progress - Edesa is progressing with the manufacturing of its dermatology drug candidate, EB06, for a Phase 2 study in moderate-to-severe nonsegmental vitiligo, with recruitment expected to begin midyear 2026, pending regulatory approvals [2][3]. - The company is evaluating subgroup data for additional efficacy signals in its respiratory program following positive results from a Phase 3 study of paridiprubart in patients with Acute Respiratory Distress Syndrome [2][3]. Research and Development - Research and development expenses increased by $0.1 million to $1.1 million for the three months ended December 31, 2025, primarily due to increased manufacturing-related activities for the EB06 program [7]. - General and administrative expenses rose by $0.3 million to $1.2 million for the same period, mainly due to an increase in noncash share-based compensation [7]. Upcoming Events - Edesa plans to participate in several upcoming scientific and medical conferences, including the Global Vitiligo Foundation Annual Scientific Symposium on March 26, 2026, and the American Thoracic Society 2026 International Conference from May 15-20, 2026 [8].

Core Insights - Edesa Biotech, Inc. reported financial results for the fiscal year ended September 30, 2025, highlighting advancements in its clinical programs and financial performance [1][4]. Financial Performance - Total operating expenses increased by $0.9 million to $7.9 million for the year ended September 30, 2025, compared to $7.0 million for the prior year [4]. - Edesa reported a net loss of $7.2 million, or $1.27 per common share, compared to a net loss of $6.2 million, or $1.93 per common share, for the year ended September 30, 2024 [5]. - Cash and cash equivalents at September 30, 2025, were $10.8 million, with working capital of $10.4 million [6]. Clinical Developments - The company initiated manufacturing activities for a Phase 2 study of EB06, an anti-CXCL10 monoclonal antibody, targeting moderate-to-severe nonsegmental vitiligo, with recruitment expected to begin by mid-2026 [2]. - A Phase 3 study of paridiprubart (EB05) met primary and secondary endpoints with statistical significance, and the company is exploring partnerships for its development and commercialization [2][3]. Strategic Initiatives - Edesa's CEO emphasized the company's strategy to advance both dermatology and respiratory assets, aiming to deliver transformative therapies to patients with high unmet medical needs [3]. - The CFO noted that the company strengthened its balance sheet and extended its Canadian government funding agreement to support manufacturing and development for its respiratory program [3]. Research and Development Expenses - Research and development expenses increased by $0.8 million to $3.7 million for the year ended September 30, 2025, primarily due to increased manufacturing-related activities and preparations for the Phase 2 clinical study of EB06 [7]. - General and administrative expenses rose by $0.1 million to $4.2 million, mainly due to increased noncash share-based compensation [7]. Future Outlook - Edesa plans to participate in one-on-one meetings during JP Morgan week starting January 12, 2026, to engage with potential strategic and government partners [7].

Core Viewpoint - Edesa Biotech, Inc. is advancing its clinical-stage biopharmaceutical development, particularly focusing on its vitiligo drug candidate EB06, while reporting financial results that reflect a strategic pivot in operational activities towards this program [1][4]. Financial Overview - For the three months ended March 31, 2025, total operating expenses decreased by $0.6 million to $1.6 million compared to $2.2 million for the same period in 2024 [7] - The company reported a net loss of $1.6 million, or $0.30 per common share, for the quarter, an improvement from a net loss of $1.9 million, or $0.58 per common share, for the same quarter last year [8] - For the six months ended March 31, 2025, total operating expenses decreased by $0.6 million to $3.5 million compared to $4.1 million for the same period in 2024 [9] - The net loss for the six months was $3.2 million, or $0.74 per common share, compared to a net loss of $3.5 million, or $1.12 per common share, for the same period last year [11] Business Development - The company completed a $15 million equity financing to support the development of EB06, an anti-CXCL10 monoclonal antibody for vitiligo [2] - Edesa has initiated outreach to potential investigators and manufacturing activities to support U.S. regulatory approval for a Phase 2 study in moderate-to-severe nonsegmental vitiligo patients [2][6] - The planned Phase 2 study for EB06 is already approved in Canada, with drug manufacturing data expected to be submitted to the FDA in the second half of 2025 [6] Research and Development - Research and development expenses decreased by $0.7 million to $0.5 million for the three months ended March 31, 2025, primarily due to decreased external research expenses related to the investigational drug paridiprubart [9][16] - General and administrative expenses increased by $0.2 million to $1.2 million for the three months ended March 31, 2025, mainly due to increased salaries and related costs [9] Cash Position - As of March 31, 2025, Edesa had cash and cash equivalents of $13.9 million and working capital of $13.5 million [12]